Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04608903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Sulforaphane for Patients With Chronic Kidney Disease

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 31, 2024 to Dec 31, 2026v7
  2. Enrollment target: 122 to 25v6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jul 31, 2024 to Dec 31, 2024
    • Study description revised
    • Site details revised
  3. Primary completion date: Dec 2022 to Dec 31, 2023
    • Study completion date: Dec 2022 to Jul 31, 2024
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Dec 2021 to Dec 2022
    • Start date changed from estimate of Sep 2021 to Dec 1, 2021
    • Site details revised
    v4
  5. Primary completion date: Apr 2021 to Dec 2021
    • Start date: Jan 2021 to Sep 2021
    • Study description revised
    v3
  6. Primary endpoints revised (2)
    • Eligibility criteria shortened, about 141 words
    • Study description shortened, about 507 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with Chronic Kidney Disease (CKD) have many complications associated with inflammation, oxidative stress and intestinal dysbiosis, which are closely related to the progression of kidney failure and cardiovascular disease. Sulforaphane, an isothiocyanate found in cruciferous vegetables (Family: Brassicaceae) is recognized as one of the most important activators of erythroid nuclear factor 2 related to factor 2 (Nrf2). However, clinical evidence to assess the effects of sulforaphane in patients with CKD is scarce, and there are no studies that have investigated its effects on the expression of genes and markers related to inflammation in these patients. Thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of sulforaphane on transcription factors and inflammatory markers in patients with CKD.
Trial Details
NCT Number NCT04608903
Lead Sponsor Universidade Federal Fluminense
Conditions
(from sponsor)		 Chronic Kidney Disease
Related terms Renal Insufficiency, Chronic
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov